Cost-Effectiveness Analysis of Serplulimab Combined with Nab-Paclitaxel Plus Carboplatin Compared to Nab-Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer in China

Yao H, Xu K, Yu M, Wang X, Lu Y, Li X, Wu H

Risk Management and Healthcare Policy 2025, 18:1309-1321

Published Date: 15 April 2025